Clinical Trials

Committed to Immuno-Oncology research

The Bristol-Myers Squibb Immuno-Oncology (I-O) portfolio consists of novel agents in development that are designed to target various immune mechanisms that may enhance antitumor immune response. We are investigating the potential of I-O, including combinations of I-O agents, in a wide range of cancers with the hope of optimizing clinical outcomes.